[en] Schizophrenia is associated with an increased risk of metabolic disorders such as diabetes, dyslipidaemia and the metabolic syndrome. The prevalence of type 2 diabetes in schizophrenic patients is at least twice that of the general population. Around 40 percent of patients meet criteria for the metabolic syndrome. Recently there is a growing concern on the metabolic side effects of treatment with second generation antipsychotics. According to various studies, including a prospective study performed in Flanders, treatment with clozapine and olanzapine has the highest metabolic risk, followed by quetiapine and risperidone. Amisulpride, ziprasidone and aripiprazole appear to have a low metabolic risk. Appropriate care, taking into account the possible improvement of the metabolic risks factors, is important to reduce morbidity and mortality in schizophrenic patients treated with antipsychotic medications.
Disciplines :
Psychiatry Endocrinology, metabolism & nutrition
Author, co-author :
Hanssens, L.; Université de Liège - ULiège > Département des Sciences de la Santé publique
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
van Winkel, R.
Van Eyck, D.
Reginster, Jean-Yves ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
De Hert, M.
Language :
French
Title :
Le cerveau au centre des regulations metaboliques: anomalies chez les patients schizophrenes traites par antipsychotiques atypiques.
Alternative titles :
[en] Brain in the core of metabolic regulations: disorders in schizophrenic patients treated with atypical antipsychotics
Publication date :
2008
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Yamada T, Oka Y, Katagiri H. - Inter-organ metabolic communication involved in energy homeostasis : Potential therapeutic targets for obesity and metabolic syndrome. Pharmacol Ther, 2008, 117, 188-198.
Morrison CD, Berthoud HR. - Neurobiology of nutrition and obesity. Nutr Rev, 2007, 65, 517-534.
Buijs RM, Kreier F. - The metabolic syndrome : a brain disease ? J Neuroendocrinol, 2006, 18, 715-716.
Scheen AJ, Seutin V, Van Gaal LF. - Le système endocannabinoïde dans le cerveau ... et ailleurs. Rev Med Liège, 2008, 63, 364-371.
Davis JM, Chen N, Glick ED. - A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry, 2003, 60, 553-564.
Leucht S, Barnes TR, Kissling W, et al. - Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized controlled trials. Am J Psychiatry, 2003, 160, 1209-1222.
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. - Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 2004, 27, 596-601.
Newcomer JW. - Second-generation (atypical) antipsychotics and metabolic effects : a comprehensive literature review. CNS Drugs, 2005, 19, 1-93.
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. - Follow-up Report on the Diagnosis of Diabetes Mellitus. Diabetes Care, 2003, 26, 3160-3167.
Scheen AJ, Luyckx FH, Lefèbvre PJ. - Comment j'explore... Le syndrome métabolique par sa nouvelle définition dite de «consensus». Rev Med Liège, 2006, 61, 48-52.
Grundy SM, Cleeman JI, Daniels SR, et al. - Definition and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005, 112, 2735-2752.
De Hert M, Van Winkel R, Van Eyck D, et al. - Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Mental Health, 2006, 27, 2-14.
Thakore JH, Mann JN, Vlahos I, et al. - Increased visceral fat distribution in drug-na'ive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord, 2002, 26, 137-141.
Meduna L, Gerty F, Urse V. - Biochemical disturbances in mental disorders. Arch Neurol Psychiatry, 1942, 47, 38-52.
Jin H, Meyer JM, Jeste DV. - Atypical antipsychotics and glucose dysregulation: a systematic review. Schizophr Res, 2004, 71, 195-212.
Newcomer JW. - Metabolic considerations in the use of antipsychotic medications: A review of recent evidence. J Clin Psychiatry, 2007, 68, 20-27.
De Nayer A, De Hert M, Scheen A, et al. - Conference report: Belgian consensus on metabolic problems associated with second-generation antipsychotics. Int J Psychiatry Clin Pract, 2005, 9, 130-137.
Elias AN, Hofflich H. - Abnormalities in glucose metabolism in patients with schizophrenia treated with atypical antipsychotic medications. Am J Med, 2008, 121, 98-104.
Scheen AJ, De Hert M. - Diabète sucré iatrogène : l'exemple des antipsychotiques atypiques. Rev Med Liège, 2005, 60, 455-460.
Scheen AJ, De Hert M. - Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab, 2007, 33, 169-175.
Van Winkel R, De Hert M, Wampers M, et al. - Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychtics in patients withj schizophrenia and schizoaffective disorder. J Clin Psychiatry, 2008, 69, 472-479.
Brown S. - Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry, 1997, 171, 502-508.
Brown S, Inskip H, Barraclough B. - Causes of the excess mortality of schizophrenia. Br J Psychiatry, 2000, 177, 212-217.
Dixon L, Postrado L, Delahanty J, et al. - The association of medical comorbidity in schizophrenia with poor physical and mental health. J Nerv Ment Dis, 1999, 187, 496-502.
Lyketsos CG, Dunn G, Kaminsky MJ, Breakey WR. - Medical comorbidity in psychiatric inpatients: relation to clinical outcomes and hospital length of stay. Psychosomatics, 2002, 43, 24-30.
Robinson DG, Woerner MG, Alvir JM, et al. - Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. Schizophr Res, 2002, 57, 209-219.
Weiden PJ, Mackell JA, Mc Donnell D. - Obesity as a risk factor for antipsychotic non-compliance. Schizophr Res, 2004, 66, 51-57.
Van Gaal LF, Mertens IL, De Block CE. - Mechanisms linking obesity with cardiovascular disease. Nature, 2006, 444, 875-880.
Wirshing DA, Meyer JM. - Obesity in patients with schizophrenia. In: Meyer JM, Nasrallah H, eds. Medical Illness and Schizophrenia. Washington DC : American Psychiatric Press Inc, 2003, 39-58.
Baptista T. - Body weight gain induced by antipsychotic drugs: mechanisms and management. Acta Psychiatr Scand, 1999, 100, 3-16.
Allison DB, Mentore LJ, Heo M, et al. - Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry, 1999, 156, 1686-1696.
De Hert M, Van Winkel R, Van Eyck D, et al. - Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res, 2006, 83, 87-93.
Van Winkel R, De Hert M, Van Eyck D, et al. - Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods. J Clin Psychiatry, 2006, 67, 1493-1500.
Mukherjee S, Deina P, Bocola V, et al. - Diabetes mellitus in schizophrenic patients. Compr Psychiatry, 1996, 37, 68-73.
Subramaniam M, Chong SA, Pek E. - Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry, 2003, 48, 345-347.
Jin H, Meyer JM, Jeste DV. - Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 publisched cases. Ann Clin Psychiatry, 2002, 14, 59-64.
DuMouchel W, Fram D, Yang X, et al. - Antipsychotics, glycemia disorders, and life-threatening diabetic events : a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004). Ann Clin Psychiatr, 2008, 20, 21-31.
Gianfrancesco FD, Grogg AL, Mahmoud RA, et al. - Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. J Clin Psychiatry, 2003, 63, 920-930.
Henderson DC. - Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs, 2002, 16, 77-89.
Koro CE, Fedder DO, L'Italien G J, et al. - Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ, 2002, 325, 243-245.
De Hert M, Van Eyck D, Hanssens L, et al. - Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur Psychiatry, 2006, 21, 224-226.
Hedenmalm K, Hagg S, Stahl M, et al. - Glucose intolerance with atypical antipsychotics. Drug Saf, 2002, 25, 1107-1116.
Casey DE, Haupt DW, Newcomer JW, et al. - Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patient with schizophrenia. J Clin Psychiatry, 2004, 65, 4-18.
Melkersson K, Dahl ML. - Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs, 2004, 64, 701-723.
Bushe CJ, Leonard BE. - Blood glucose and schizophrenia : a systematic review of prospective randomized clinical trials. J Clin Psychiatry, 2007, 68, 1682-1690.
Ader M, Kim SP, Catalano KJ, et al. - Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease. A placebo-controlled study of olanzapine and risperidone in dogs. Diabetes, 2005, 54, 862-871.
Scheen AJ. - Le syndrome métabolique : physiopathologie et traitement. In : Athérosclérose Athérothrombose (Eds : Kulbertus H., Van Mieghem W.), Transmed Medical Communications, Lubbeek, Belgium, 2006, 161-190.
Heiskanen T, Niskanen L, Lyytikainen R, et al. - Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry, 2003, 64, 575-579.
Cohn T, Prud'homme D, Streiner D, et al. - Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry, 2004, 49, 753-760.
McEvoy JP, Meyer JM , Goff DC, et al. - Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res, 2005, 80, 19-32.
Rietzschel E, De Buyzere M, De Bacquer D, et al. - Metabolic syndrome, a map of the cardiovascular damage. Results from the Asklepios study in 2528 patients apparently healthy 35-55 year old subjects (Abstract). Eur Heart J, 2005, 26, 110.
Meyer JM, Koro CE. - The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res, 2004, 7, 1-17.
Scheen AJ. - Comment j'explore ... Le risque cardio-vasculaire absolu à 10 ans : de Framingham 1998 à SCORE 2003. Rev Med Liège, 2004, 59, 460-466.
Hanssens L, De Hert M, Kalnicka D, et al. - Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia. Int J Clin Psychopharmacol, 2007, 22, 43-49.
De Hert M, Kalnicka D, Van Winkel R, et al. - Treatment with rosuvastatin for severe dyslipidaemia in patients with schizophrenia. J Clin Psychiatry, 2006, 67, 1889-1896.
De Hert M, Hanssens L, Van Winkel R, et al. - A case series: evaluation of the metabolic safety of aripiprazole. Schizophr Bull, 2006, 29, 2329-2330.
De Hert M, Hanssens L, Van Winkel R, et al. - Reversibility of antipsychotic treatment related diabetes in patients with schizophrenia. A case series of switching to aripiprazole. Diabetes Care, 2006, 29, 2329-2330.
Scheen AJ, Radermecker RP, Philips JC, et al. - Le traitement du diabète de type 2 : entre insulinosensibilisateurs et insulinosécrétagogues. Rev Med Liège, 2007, 62 (No spécial Synthèse 2007), 40-46.
